AU2011241478B2 - Compound for treatment of respiratory condition or disease - Google Patents

Compound for treatment of respiratory condition or disease Download PDF

Info

Publication number
AU2011241478B2
AU2011241478B2 AU2011241478A AU2011241478A AU2011241478B2 AU 2011241478 B2 AU2011241478 B2 AU 2011241478B2 AU 2011241478 A AU2011241478 A AU 2011241478A AU 2011241478 A AU2011241478 A AU 2011241478A AU 2011241478 B2 AU2011241478 B2 AU 2011241478B2
Authority
AU
Australia
Prior art keywords
ethoxy
isoxazole
piperidin
pyridazin
benzo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2011241478A
Other languages
English (en)
Other versions
AU2011241478A1 (en
Inventor
John Nicholas Lambert
Jane Ryan
Janet Marie Wilson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biota Scientific Management Pty Ltd
Original Assignee
Biota Scientific Management Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2010901601A external-priority patent/AU2010901601A0/en
Application filed by Biota Scientific Management Pty Ltd filed Critical Biota Scientific Management Pty Ltd
Priority to AU2011241478A priority Critical patent/AU2011241478B2/en
Publication of AU2011241478A1 publication Critical patent/AU2011241478A1/en
Application granted granted Critical
Publication of AU2011241478B2 publication Critical patent/AU2011241478B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Otolaryngology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
AU2011241478A 2010-04-15 2011-04-14 Compound for treatment of respiratory condition or disease Ceased AU2011241478B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2011241478A AU2011241478B2 (en) 2010-04-15 2011-04-14 Compound for treatment of respiratory condition or disease

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
AU2010901601A AU2010901601A0 (en) 2010-04-15 Compound for the treatment of respiratory condition or disease
AU2010901601 2010-04-15
PCT/AU2011/000434 WO2011127538A1 (en) 2010-04-15 2011-04-14 Compound for treatment of respiratory condition or disease
AU2011241478A AU2011241478B2 (en) 2010-04-15 2011-04-14 Compound for treatment of respiratory condition or disease

Publications (2)

Publication Number Publication Date
AU2011241478A1 AU2011241478A1 (en) 2012-11-01
AU2011241478B2 true AU2011241478B2 (en) 2016-12-01

Family

ID=44788654

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2011241478A Ceased AU2011241478B2 (en) 2010-04-15 2011-04-14 Compound for treatment of respiratory condition or disease

Country Status (16)

Country Link
US (1) US20110257192A1 (enExample)
EP (1) EP2558097B1 (enExample)
JP (1) JP6148618B2 (enExample)
KR (1) KR20130106267A (enExample)
CN (2) CN105560245A (enExample)
AU (1) AU2011241478B2 (enExample)
BR (1) BR112012026244A2 (enExample)
CA (1) CA2796207A1 (enExample)
EA (1) EA025224B1 (enExample)
ES (1) ES2647223T3 (enExample)
IL (1) IL222244A0 (enExample)
MX (1) MX2012011938A (enExample)
NZ (1) NZ603040A (enExample)
SG (2) SG184430A1 (enExample)
WO (1) WO2011127538A1 (enExample)
ZA (1) ZA201207696B (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2909057C (en) 2013-04-12 2022-03-22 Obschestvo S Ogranichennoi Otvetstvennostiyu "Pharmenterprises" Glutarimide derivatives, use thereof, pharmaceutical composition based thereon and methods for producing glutarimide derivatives
BR112016029942A2 (pt) 2014-06-20 2017-08-22 Aviragen Therapeutics Inc composto, forma de base livre cristalina anidra, composição farmacêutica, método para fabricação de uma forma de base livre cristalina, método de tratamento de uma infecção viral, método de tratar, aliviar, prevenir ou reduzir os sintomas ou exacerbações de asma ou doença pulmonar obstrutiva crônica e método de tratamento de doença mão, pé e boca
WO2024192151A2 (en) * 2023-03-13 2024-09-19 Altesa BioSciences, Inc. Method of dosing vapendavir to treat enterovirus infections

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002050045A1 (en) * 2000-12-18 2002-06-27 Biota Scientific Management Pty Ltd Antiviral agents
WO2009143571A1 (en) * 2008-05-27 2009-12-03 Biota Scientific Management Pty Ltd Antiviral salts
WO2010009288A1 (en) * 2008-07-17 2010-01-21 Schering Corporation Compositions and uses of antiviral active pharmaceutical agents

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2475971A1 (en) * 2002-02-14 2003-08-21 Viropharma Incorporated Methods of reducing rhinovirus contagion and related compositions
ATE399549T1 (de) * 2003-02-21 2008-07-15 Apodemus Ab Behandlung von durch das ljungan-virus ausgelösten erkrankungen durch verwendung von pleconaril
US9308199B2 (en) * 2004-04-29 2016-04-12 Honeywell International Inc. Medicament formulations
US20060069124A1 (en) * 2004-09-07 2006-03-30 Rao P S Use of MDL-100,907 for treatment of allergic and eosinophil mediated diseases
AR057623A1 (es) * 2005-11-28 2007-12-05 Omega Bio Pharma H K Ltd Materiales y metodos para el tratamiento de las infecciones virales

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002050045A1 (en) * 2000-12-18 2002-06-27 Biota Scientific Management Pty Ltd Antiviral agents
WO2009143571A1 (en) * 2008-05-27 2009-12-03 Biota Scientific Management Pty Ltd Antiviral salts
WO2010009288A1 (en) * 2008-07-17 2010-01-21 Schering Corporation Compositions and uses of antiviral active pharmaceutical agents

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
Brown, R. N. "2-Ethoxybenzoxazole as a bioisosteric replacement of an ethyl benzoate group in a human rhinovirus (HRV) capsin binder" Bioorganic and Medicinal Chemistry Letters (2005), vol. 15, ;pages 2015-2055 *
DE PALMA, A. M. et al. "Selective Inhibitors of Picornavirus Replication" Medicinal Research Reviews (2008) vol. 28, no. 6, pages 823-884 *
MALLIA, P. et al. "Exacerbations of Asthma and Chronic Obstructive Pulmonary Disease (COPD): Focus on Virus Induced Exacerbations" Current Pharmaceutical Design (2007) vol. 13, pages 73-97 *
ROHDE, G. et al. "Drug Targets in Rhinoviral Infections" Infectious Disorders - Drug Targets (2009) vol. 9, no. 2, pages 126-132 *

Also Published As

Publication number Publication date
JP2013523844A (ja) 2013-06-17
NZ603040A (en) 2015-03-27
WO2011127538A1 (en) 2011-10-20
EP2558097A4 (en) 2013-09-11
JP6148618B2 (ja) 2017-06-14
MX2012011938A (es) 2013-01-28
ES2647223T3 (es) 2017-12-20
CN105560245A (zh) 2016-05-11
EP2558097A1 (en) 2013-02-20
SG184430A1 (en) 2012-11-29
CA2796207A1 (en) 2011-10-20
ZA201207696B (en) 2014-03-26
US20110257192A1 (en) 2011-10-20
EA201201416A1 (ru) 2013-03-29
EP2558097B1 (en) 2017-10-25
IL222244A0 (en) 2012-12-31
EA025224B1 (ru) 2016-12-30
CN102844032A (zh) 2012-12-26
KR20130106267A (ko) 2013-09-27
BR112012026244A2 (pt) 2016-07-12
SG10201502391WA (en) 2015-05-28
AU2011241478A1 (en) 2012-11-01

Similar Documents

Publication Publication Date Title
US11324708B1 (en) Niclosamide formulations for treating disease
JP7169693B2 (ja) 呼吸器疾患の治療
Alipour et al. Pulmonary drug delivery: an effective and convenient delivery route to combat COVID-19
CN1289086C (zh) 抗疟治疗药物的新用途
US20230190685A1 (en) Formulation
CN117695284A (zh) 冠状病毒感染的治疗
JP2024545086A (ja) 抗ウイルス治療剤及びその使用
AU2011241478B2 (en) Compound for treatment of respiratory condition or disease
CN116744934A (zh) 用于治疗病毒性呼吸疾病的吸入性他汀类药物
KR102875179B1 (ko) 폴리클로날 면역글로불린을 사용한 급성 악화를 예방하거나 치료하기 위한 방법 및 조성물
CA3040828A1 (en) Inhalable powder composition comprising il-13 antibody
JP2023524064A (ja) ウイルス感染を治療又は予防するためのクロファジミン組成物及び方法
TW200927193A (en) Inhaled aztreonam lysine for the treatment of deficits in health-related quality-of-life in lung diseases
US20230192634A1 (en) Antiviral Compounds for Use in the Treatment of Coronavirus Infection
Saha Inhaled dry powder to treat respiratory infections
US20220304959A1 (en) Treatment of long haulers syndrome with niclosamide
HK40058742B (zh) 呼吸性疾病的治疗
HK1075619B (en) New uses for anti-malarial therapeutic agents

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired